J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dowell, J.
Right arrow Articles by Berger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dowell, J.
Right arrow Articles by Berger, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

JA Dowell, J Korth-Bradley, H Liu, SP King, and MS Berger

The purpose of this study was to characterize the pharmacokinetics of gemtuzumab ozogamicin (Mylotarg; Wyeth-Ayerst Laboratories, St. Davids, PA) in patients with acute myeloid leukemia (AML) in first relapse. Gemtuzumab ozogamicin is an antibody-chemotherapeutic conjugate characterized as antibody-targeted chemotherapy, consisting of an engineered human anti-CD33 antibody (hP67.6) linked to a potent cytotoxic agent, N-acetyl-gamma calicheamicin DMH. The pharmacokinetics of gemtuzumab ozogamicin was evaluated in 59 adult AML patients in first relapse, enrolled in a phase II study. Plasma was collected following each dose at specified times, and the pharmacokinetics was characterized by measures of hP67.6, total calicheamicin derivatives, and unconjugated calicheamicin derivatives. After administration of the first 9 mg/m2 dose of gemtuzumab ozogamicin, the pharmacokinetic parameters (mean +/- SD) of hP67.6 following the first dose were as follows: peak plasma concentration, 2.86 +/- 1.35 mg/L; AUC, 123 +/- 105 mg x h/L; t 1/2, 72.4 +/- 42.0 hours; and clearance, 0.265 +/- 0.229L/h. Increased concentrations were observed after the second dose and are believed to be due to a decrease in clearance by CD33-positive blast cells, a result of the reduced tumor burden following the first dose. The concentration profiles of calicheamicin followed the same time course as hP67.6, evidence that calicheamicin remained conjugated to the antibody and delivered to leukemic cells. No relationship was found between plasma concentration and response at the recommended dose. The pharmacokinetics of gemtuzumab ozogamicin has been characterized in AML patients receiving doses at the proposed therapeutic level.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
J. Laubach and A. V. Rao
Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly
Oncologist, October 1, 2008; 13(10): 1097 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Bornhauser, T. Illmer, U. Oelschlaegel, J. Schetelig, R. Ordemann, M. Schaich, M. Hanel, U. Schuler, C. Thiede, A. Kiani, et al.
Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia
Clin. Cancer Res., September 1, 2008; 14(17): 5585 - 5593.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. B. Walter, B. W. Raden, D. M. Kamikura, J. A. Cooper, and I. D. Bernstein
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
Blood, February 1, 2005; 105(3): 1295 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Tassone, V. S. Goldmacher, P. Neri, A. Gozzini, M. A. Shammas, K. R. Whiteman, L. L. Hylander-Gans, D. R. Carrasco, T. Hideshima, R. Shringarpure, et al.
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
Blood, December 1, 2004; 104(12): 3688 - 3696.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. Buckwalter, J. A. Dowell, J. Korth-Bradley, B. Gorovits, and P. R. Mayer
Pharmacokinetics of Gemtuzumab Ozogamicin as a Single-Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
J. Clin. Pharmacol., August 1, 2004; 44(8): 873 - 880.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Tassone, A. Gozzini, V. Goldmacher, M. A. Shammas, K. R. Whiteman, D. R. Carrasco, C. Li, C. K. Allam, S. Venuta, K. C. Anderson, et al.
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells
Cancer Res., July 1, 2004; 64(13): 4629 - 4636.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. F. DiJoseph, D. C. Armellino, E. R. Boghaert, K. Khandke, M. M. Dougher, L. Sridharan, A. Kunz, P. R. Hamann, B. Gorovits, C. Udata, et al.
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
Blood, March 1, 2004; 103(5): 1807 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. B. Walter, B. W. Raden, T. C. Hong, D. A. Flowers, I. D. Bernstein, and M. L. Linenberger
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
Blood, August 15, 2003; 102(4): 1466 - 1473.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Clinical Pharmacology